Headline: Danaher to acquire Abcam
Acquiror: Danaher Corporation
Target: Abcam plc
Target Services: Life science research tools
Valuation: $24.00 per share
Country: United Kingdom
Target Industry: Life Sciences
Rationale: Abcam’s extensive expertise in the supply of highly validated antibodies, reagents, biomarkers, and assays offers a synergistic alignment with Danaher’s existing capabilities.
Summary: Danaher Corporation announces the acquisition of Abcam plc for $24.00 per share in cash, enhancing its presence in life sciences and supporting its strategy to accelerate drug discovery through innovative research tools.